Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 15/20 | 0.41 |
| ▸ | CTSK | P43235 | 13/20 | 0.41 |
| ▸ | CTSL | P07711 | 3/20 | 0.41 |
| ▸ | CTSB | P07858 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15083450 | 0.91 | CTSS (0.41) | CTSSCTSKCTSLCTSBCYP1A2 | |
| SCHEMBL23056474 | 0.91 | CTSS (0.42) | CTSSCTSKCTSLCTSBCYP1A2 | |
| SCHEMBL23056600 | 0.88 | CYP1A2 (0.38) | CTSSCTSKCTSLCTSBCYP1A2 | |
| SCHEMBL16288452 | 0.87 | CTSS (0.39) | CTSSCTSKCTSLCTSBCYP1A2 | |
| SCHEMBL16288449 | 0.87 | CTSS (0.39) | CTSSCTSKCTSLCTSBCYP1A2 | |
| SCHEMBL16288450 | 0.87 | CTSS (0.39) | CTSSCTSKCTSLCTSBCYP1A2 | |
| SCHEMBL23056574 | 0.83 | PPARA (0.39) | CTSSCTSKCTSLCTSBCYP1A2 | |
| SCHEMBL15083189 | 0.81 | CTSS (0.42) | CTSSCTSKCTSLCTSBCYP1A2 | |
| SCHEMBL16310468 | 0.78 | CYP1A2 (0.38) | CTSSCTSKCTSLCTSBCYP1A2 | |
| SCHEMBL23056579 | 0.78 | CYP1A2 (0.38) | CTSSCTSKCTSLCTSBCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210061860-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2021-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210061860-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | VIP, NGLY1, GLP1R | CTSS 273/4885CTSK 188/4885CTSL 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.